With the annual J.P. Morgan Healthcare Conference pivoting to a virtual format again in 2022, we will be hosting a lineup of virtual events and reports aligned with the industry’s biggest conference.
Complimentary Virtual Meeting with our Global Team
Connect with Baker McKenzie’s life sciences and healthcare lawyers around the world! Partake in a complimentary virtual meeting covering a range of areas of law to help grow and expand your business internationally. Contact your Baker McKenzie contact or Grace Gato to arrange a meeting. Please indicate your business need, geographies of interest and any other relevant information.
Funding Growth and the Future of Life Sciences
How do life sciences companies intend to leverage new and existing sources of growth? Explore the trajectory of life sciences transactions in our latest report that focuses on:
The enduring robust appetite for M&A, carve-outs, divestitures, partnerships, licensing and collaboration agreements
The rising focus on sustainability goals aligned with pursuing deals linked to corporate power purchase agreements (PPAs) and green financing
Continued VC investment and increasing appetitive from private equity sponsors in pre-revenue stages
This report explores the defining characteristics of pharmaceutical and biotech transactions in 2022 and recommends a framework to understand the legal complexity in a fast-evolving sector and at a uniquely opportunistic time. As you identify key opportunities to transform your business responsibly and strategically, our new report will help you navigate legal complexity and stress test plans in an evolving transactional landscape.
Virtual Events: January – February 2022
To register, please click on the relevant links or reach out to the contacts listed.
A panel of trade compliance experts will discuss topics such how the cannabis industry can be more trade compliant, how to navigate the multi-jurisdictional variances in customs laws, how to reduce the risks associated with the import and export of cannabis and how to identify and mitigate sanctions risks. We will also showcase our interactive global dashboard, which provides an overview of import and export rules in over 100 markets.
As a result of COVID-19, healthcare and life sciences is not only the fastest growing industry in the world but it is very much in the spotlight. Interact with a case study to explore compliance, litigation and enforcement risks resulting from the evolving landscape.
Beyond resilience, the supply chains of the future are expected to be sustainable, embracing ESG principles. For the healthcare and life sciences sector, this means integrating corporate governance and inclusion & diversity into the value chain. It also means looking at access to medicines and medical devices from an ESG perspective and exploring alternatives such as corporate power purchase agreements. Our panel of experts will discuss how these trends are set to advance and transform the healthcare and life sciences supply chain in 2022 and beyond.
Vanina Caniza is a partner in Baker McKenzie’s Buenos Aires office and the Global Chair of the Healthcare & Life Sciences Group. She advises a range of multinational, Latin America and Argentine clients in a variety of corporate and commercial law matters, with extensive experience in corporate compliance, commercial agreements, mergers & acquisitions and regulatory advice. Vanina has extensive knowledge in the pharmaceutical, biotech and medical device sectors. She completed postgraduate courses on Biotechnology at Universidad Torcuato di Tella (Buenos Aires) and on Health Law at Universidad de Buenos Aires. She was previously the Latin America Leader of the Healthcare & Life Sciences Group and also sits on the Steering Committee of the Firm’s Latin America Corporate Compliance Group. She is currently a professor in the CEC Compliance & Ethics Certification (AAEC-UCEMA).
Randall Sunberg is a partner in the Corporate & Securities Practice Group and the Life Sciences Industry Group. He also serves as the co-head of the North America Life Sciences practice. Randy structures and negotiates complex collaborations, mergers and acquisitions, divestitures, joint ventures, and corporate partnering and licensing transactions, as well as equity investments and royalty monetization transactions for clients ranging from biotech startups to multinational pharmaceutical companies.
Henrique Kruger Frizzo joined the firm in 2004 and became a partner in 2014. He is the leader of the Life Sciences group and also integrates the Public and Regulatory Law group. He acts in the preparation of legal opinions and consultations on topics of his expertise, including tenders and contracts with the government, public service concession contracts and public-private partnerships. He has experience in complex negotiations with the government and assists clients in structuring effective government relationships. He also acts in the identification of irregularities and illicit acts in contracts and relationships with the government and in the area of sales to defense and public security agencies, including in the structuring of technological compensation agreements.
In the Healthcare sector, he advises pharmaceutical, medical device and other companies in the sector on a wide range of matters, including transactions involving commercial agreements and complex negotiations with the government and health technology transfer agreements. He also advises clients on market access strategies, including procedures for the incorporation of new health technologies into SUS and ANS, and represents companies in CMED administrative proceedings. Henrique prepares consultations involving clinical research and regulatory issues, reviews promotional materials, and acts in administrative litigation involving local health authorities and ANVISA. Additionally, he provides support in compliance issues, digital health and analysis of the constitutionality/legality of legislation. Due to his expertise, he participates in the drafting of bills of law and regulations for the industry.
In Public Law, Government Affairs, Regulatory and Compliance, he has extensive experience in corporate investigations, with a focus on government procurement and corruption, and their respective consequences in the civil and administrative areas. We assist clients in defining strategic decisions regarding the results of the investigation and participate in the defense before or during the negotiation with the civil and administrative police authorities responsible for the cases.
Roel Meers is a partner in the Corporate Finance Practice Group of Baker McKenzie's Brussels office. He is mentioned in leading legal directories such as Chambers and Legal 500.
Jane E. Hobson is a partner in Baker Mckenzie's London office. She works in the Firm's London Corporate group, is a member of the Global M&A Practice Group, and focuses on cross-border mergers and acquisitions, licensing transactions and joint ventures in the pharmaceutical and healthcare sector.
Aarthi Belani is a partner in Baker McKenzie’s Palo Alto office. Aarthi’s practice focuses on M&A and venture deals in the tech and life sciences arena. She represents strategic acquirers, especially in cross-border deals, emerging growth technology companies, venture capital funds, and corporate venture capital. She has also represented the sell-side and advised on health care, financial services, and impact investment deals.
Prior to joining Baker McKenzie, Aarthi was a partner in the M&A practice of a top-tier international law firm. Prior to that, she was on the in-house legal team covering strategic M&A at Credit Suisse in New York, where she was also a member of the Sustainability Network, a Credit Suisse OneBank (cross-divisional) initiative to develop impact investment products. At the start of her career, Aarthi was an associate in the New York office of another top-tier international law firm for five years, where she worked on complex strategic M&A and innovative development finance.
She is a mentor for the Unreasonable Group (a program for entrepreneurs); a Leadership Committee member of How Women Lead, which is part of the campaign to increase the representation of women on corporate boards; and a director of Bidoun, a not-for-profit publishing, curatorial, and educational initiative that prints a quarterly magazine showcasing art and culture from the Middle East.
Adam Farlow is the Global Chair of our Capital Markets Practice Group. He is a New York and English qualified capital markets partner based in London. He has extensive experience in US securities laws and transaction management. He has been elected as a Life Fellow of the American Bar Foundation and serves on the Council of the American Bar Association Section of International Law.
Ben McLaughlin is a partner in Baker McKenzie's Sydney office. He has over 25 years' experience in advising leading Australian and international public companies on mergers and acquisitions (M&A) and equity capital markets. Ben invented the Baker McKenzie Healthcare MapApp, an acclaimed mobile application that enables clients to access over 5,000 pages of legal summaries. He has been recognized by Chambers for his work in Australian and international M&A matters, as well as in healthcare and life sciences. Ben has also been recognised as "Lawyer of the Year" for Life Sciences Practice in Sydney and as one of the Best Lawyers in Australia for Corporate / Corporate Governance and M&A Law, Best Lawyers 2022 Edition.
Ben is admitted to practice law in Australia and the US, and previously practised as a CPA.
Tracy Wut is the managing partner for Baker McKenzie's China and Hong Kong offices. She is experienced in mergers and acquisitions and foreign direct investments in China. She regularly acts for clients in complex cross-border transactions, in particular in the pharmaceuticals and healthcare sector, and navigates clients through various issues relating to investments in China. She has been recommended as a leading lawyer in Corporate/M&A by Chambers Global, Corporate/M&A and Life Sciences by Chambers Asia and M&A and private equity by IFLR1000. She is the co-head of the Pharmaceuticals and Healthcare Industry Group in China and Hong Kong.
